Difference between revisions of "Louise Dunn"
(→Resources) |
|||
| Line 9: | Line 9: | ||
==Resources== | ==Resources== | ||
*Robert Cockburn [http://prospect.org/article/death-dilution Death by dilution], ''[[American Prospect]]'', 20 November 2005. | *Robert Cockburn [http://prospect.org/article/death-dilution Death by dilution], ''[[American Prospect]]'', 20 November 2005. | ||
| + | *Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ (2005) [http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0020100 The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers]. ''PLoS Med'' 2(4): e100. doi:10.1371/journal.pmed.0020100 | ||
==Notes== | ==Notes== | ||
<references/> | <references/> | ||
Revision as of 10:19, 13 August 2013
Louise Dunn is Vice President, Global R&D and Portfolio Communications GlaxoSmithKline and has worked in PR for GSK since 2004. Dunn attended the University of Oxford gaining an MA Oxon, Biochemistry (1988 – 1992).
Contents
Career
- January 2011 – Present - Vice President, Global R&D and Portfolio Communications GlaxoSmithKline
- April 2008 – December 2010 - VP R&D Communications GlaxoSmithKline
- September 2004 – April 2008 - Vice President, Communications, Pharmaceuticals International and Japan GlaxoSmithKline[1]
Affiliations
- 2012 - Advisory Board Science Media Centre[2]
Resources
- Robert Cockburn Death by dilution, American Prospect, 20 November 2005.
- Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ (2005) The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers. PLoS Med 2(4): e100. doi:10.1371/journal.pmed.0020100
Notes
- ↑ LinkedIn 'Louise Dunn', accessed 4 August 2013
- ↑ Science Media Centre Advisory board, Retrieved from the Internet Archive of 24 September 2012 on 4 August 2013.
